30 results match your criteria: "Vermont Regional Cancer Center[Affiliation]"
Blood transfusions and survival after resection of cancers of the breast, colon, and lung: the need for prospective randomized trials.
Transplant Proc
December 1988
Vermont Regional Cancer Center, University of Vermont, Burlington 05401.
Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Cancer Res
September 1988
Department of Medicine, Vermont Regional Cancer Center, Burlington 05401.
Trimetrexate (TMQ; NSC 352122) is a potent inhibitor of dihydrofolate reductase with good activity against murine i.p.-implanted B16 melanoma and colon 26 tumors.
View Article and Find Full Text PDFEffect of commercial peritoneal dialysis fluids on the lytic function of lymphokine-activated killer cells.
J Biol Response Mod
August 1988
Vermont Regional Cancer Center, Burlington.
Intraperitoneal (ip) immunotherapies are often administered in saline or peritoneal dialysis solutions. In preparation for a Phase I i.p.
View Article and Find Full Text PDFSafety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists.
Semin Oncol
April 1988
Vermont Regional Cancer Center, University of Vermont, Burlington 05401.
Effect of trimethoprim, paracetamol and cimetidine on trimetrexate metabolism by rat perfused isolated livers.
J Pharm Pharmacol
November 1987
Vermont Regional Cancer Center, University of Vermont, Burlington 05405.
Trimetrexate (TMTX), a non-classical antifolate, is currently in clinical trial as an antineoplastic drug. In the rat perfused isolated liver, it undergoes extensive metabolism to two metabolites, M1 and M2, which are excreted primarily in the bile. The metabolites result from demethylation, and M1 is also glucuronidated.
View Article and Find Full Text PDF